Skip to main content
Back
TEVA logo

Teva Pharmaceutical Industries Limited

Data quality: 100%
TEVA
NYSE Healthcare Drug Manufacturers - Specialty & Generic
$28.77
▲ $0.04 (0.14%)
Mkt Cap: 33.51B
Day Range
$28.65 $29.39
52-Week Range
$12.47 $37.35
Volume
4,106,809
50D / 200D Avg
$32.63 / $23.84
Prev Close
$28.73

Price History

Financial Trends

Peer Comparison

vs Healthcare sector median (626 peers)

Metric Stock Sector Median
P/E 23.8 0.4
P/B 4.2 2.9
ROE % 21.2 3.8
Net Margin % 8.2 3.9
Rev Growth 5Y % 2.1 10.0
D/E 2.2 0.2

Analyst Price Target

Hold
$38.33 +33.2%
Low: $35.00 High: $41.00
Forward P/E
10.6
Forward EPS
$2.70
EPS Growth (est.)
+0.0%
Est. Revenue
17 B

Earnings Estimates

Period EPS Est. Revenue Est. Analysts
FY2030 $4.06
$4.01 – $4.12
19 B 1
FY2029 $3.58
$3.54 – $3.64
18 B 1
FY2028 $3.44
$2.25 – $4.45
18 B 3

Key Takeaways

Revenue grew 2.10% annually over 5 years — modest growth
ROE of 21.23% indicates high profitability
Debt/Equity of 2.20 — high leverage
Generating 1.15B in free cash flow
Cash machine — converts 81.42% of earnings into free cash flow
Capital efficient — spends only 2.90% of revenue on capex

Growth

Revenue Growth (5Y)
2.10%
Revenue (1Y)4.31%
Earnings (1Y)N/A
FCF Growth (3Y)16.77%

Quality

Return on Equity
21.23%
ROIC6.40%
Net Margin8.17%
Op. Margin12.50%

Safety

Debt / Equity
2.20
Current Ratio1.04
Interest Coverage2.35

Valuation

P/E Ratio
23.76
P/B Ratio4.24
EV/EBITDA21.94
Dividend Yield0.00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 4.31% Revenue Growth (3Y) 4.36%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 2.10% Earnings Growth (5Y) 35.60%
Profitability
Revenue (TTM) 17.26B Net Income (TTM) 1.41B
ROE 21.23% ROA 3.46%
Gross Margin 51.79% Operating Margin 12.50%
Net Margin 8.17% Free Cash Flow (TTM) 1.15B
ROIC 6.40% FCF Growth (3Y) 16.77%
Safety
Debt / Equity 2.20 Current Ratio 1.04
Interest Coverage 2.35 Dividend Yield 0.00%
Valuation
P/E Ratio 23.76 P/B Ratio 4.24
P/S Ratio 1.94 PEG Ratio -0.14
EV/EBITDA 21.94 Dividend Yield 0.00%
Market Cap 33.51B Enterprise Value 47.33B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 17.26B 16.54B 15.85B 14.93B 15.88B
Net Income 1.41B -1.64B -559.00M -2.45B 417.00M
EPS (Diluted) 1.20 -1.45 -0.50 -2.20 0.38
Gross Profit 8.94B 8.06B 7.65B 6.97B 7.59B
Operating Income 2.16B -303.00M 433.00M -2.20B 1.72B

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 40.75B 39.33B 43.48B 44.01B 47.67B
Total Liabilities 32.83B 33.61B 35.35B 35.41B 36.42B
Shareholders' Equity 7.91B 5.37B 7.51B 7.80B 10.28B
Total Debt 17.38B 18.08B 20.15B 21.56B 23.46B
Cash & Equivalents 3.56B 3.30B 3.23B 2.80B 2.17B
Current Assets 13.95B 12.55B 12.49B 12.05B 12.57B
Current Liabilities 13.46B 12.80B 12.25B 11.47B 11.03B